

Design, synthesis, *in silico* studies, and biological evaluation of novel pyrimidine-5-carbonitrile derivatives as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers

Abdulrahman M. Saleh, Hazem A. Mahdy^{a*}, Mohamed Ayman El-Zahabi^a, Ahmed B. M. Mehany^b, Mohamed M. Khalifa^{a*}, Ibrahim H. Eissa^{a*}

^a Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.

^b Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo 11884, Egypt

*** Corresponding authors:**

Ibrahim H. Eissa

Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt

Email: Ibrahimeissa@azhar.edu.eg

Hazem A. Mahdy

Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt

Email: Hazem_hady2001@azhar.edu.eg

Mohamed M. Khalifa

Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.

Email: MohamedKhalifa2321.el@azhar.edu.eg

Content

1	All the reagents, chemicals, apparatus used in chemistry section
2	Experimental of biological testing
3	Spectral data of intermediate and final target compounds (3 , 4 , 5 , 6 , 8 , 9a-d , 11a-e , and 12a-g)

All the reagents, chemicals, apparatus used in chemistry section.

All melting points had been concluded by open capillary system on Stuart melting point apparatus SMP30 and had been uncorrected. The IR spectra were certified on a Bruker FT/IR-ATR spectrometer and expressed in wave number (cm^{-1}). The ^1H NMR spectra were recorded at 400 MHz while ^{13}C NMR spectra were run at 100 MHz, on a Bruker 400 MHz-NMR spectrophotometer. TMS was used as internal standard, coupling constant (J) values were given in Hertz, chemical shifts were measured in δ (ppm) and recorded relative to ($\text{DMSO-}d_6$) solvent. The mass spectra were acquired on Varian Mat 311-A spectrometer (70 e.v.). Progress of reactions were monitored by TLC using TLC sheets coated with UV fluorescent silica gel and were visualized using UV lamp and different developing solvent system of DCM / methanol mixtures as mobile phases. Purity of the synthesized compounds was performed using a Waters Alliance 2695 HPLC, Column Thermo HYPERSIL BDS C18.

Table S-1: Signaling ratio of each signal group for compounds **11b** and **12b**.

Compound	Key groups	Total integration	Integration of the 1 st signal (%)	Integration of the 2 nd signal (%)
11b	CH ₃	3.13	1.76 (56.2)	1.37 (43.8)
	SCH ₃	3.20	1.93 (60.3)	1.27 (39.7)
	NH	1.20	0.59 (57.85)	0.43 (42.15)
	CONH	1.30	0.60	0.43

			(58.25)	(41.75)
12b	CH ₃	2.94	1.95 (66.32)	0.99 (33.67)
	SCH ₃	3.11	2.01 (64.63)	1.10 (35.36)
	NH	0.86	0.53 (61.62)	0.33 (38.37)
	CONH	0.74	0.43 (58.10)	0.31 (41.89)

Biological testing

1. *In vitro* anti-proliferative activity

MTT assay protocol was applied as described previously to assess the anti-proliferative activity of the synthesized compounds. Two human cancer cell lines (HCT-116 and MCF-7) were used in this test. At first, the cell lines were cultured in RPMI-1640 medium with 10% fetal bovine serum. Antibiotics (100 unit's/ml penicillin and 100 µg/ml streptomycin) were added at 37°C in a 5% CO₂ incubator. The cell lines were seeded in a 96-well plate at a density of 1.0 x 10⁴ cells / well at 37° C for 24 h under 5% CO₂. After incubation, the cells were treated with different concentrations of the synthesized compounds and incubated for 48 h. After 48 h of drug treatment, 20 µl of MTT solution at 5mg/ml was added and incubated for 4 h. Dimethyl sulfoxide (DMSO) in volume of 100 µl was added into each well to dissolve the purple formazan formed. The colorimetric assay was measured and recorded at absorbance of 570 nm using a plate reader (EXL 800, USA). The relative cell viability in percentage was calculated as (A₅₇₀ of treated samples/A₅₇₀ of untreated sample) X 100. The half maximal inhibitory concentration (IC₅₀) values are presented using non-linear regression analysis of the data set from three experiments with three plate wells were used for an individual concentration.

2. *In vitro* VEGFR-2 TK assay

The most active derivatives (**9d**, **11b**, **11c**, **11d**, **11e**, **12b**, **12c**, and **12d**) that exhibited promising antiproliferative activities against HCT-116 and MCF-7 cell lines were tested for its inhibitory activity against VEGFR-2 TK. Human VEGFR-2 TK ELISA kit (Enzyme-Linked

Immunosorbent Assay) was utilized in this test. At first, specific antibody for VEGFR-2 TK was seeded on a 96-well plate and 100 μL of the standard solution or the tested compound was added, all were incubated at room temperature for 2.5 h. Then washed, 100 μL of the prepared biotin antibody was added, then incubated at room temperature for an additional 1 h. and washed. Then, 100 μL of streptavidin solution was added and incubated for 45 min. at room temperature and washed again, 100 μL of TMB Substrate reagent was added and incubated for 30 min. at room temperature. 50 μL of the stop solution was added, then was read at 450 nm immediately. The standard curve was drawn, concentrations on the X-axis and the absorbance on the Y-axis.

3. Flow cytometry analysis for cell cycle

To investigate the effect of the synthesized compounds on the various phases of the cell cycle in HCT-116 cells, flow cytometric analysis of cell cycle was performed using Epics XL-MCL™ Flow Cytometer according to flow cytometric analysis technique.

Flow Cytometry Kit for Cell Cycle Analysis (ab139418_Propidium Iodide Flow Cytometry Kit/BD) was used in this test. HCT-116 cells were treated with compound **11e** ($1.14 \pm 0.01 \mu\text{M}$) for 24 h. Then, the cells were fixed in 70% ethanol at 4 °C for 12 h. After that, the cells were washed with cold PBS, incubated with 100 μl RNase A at 37 °C for 30 min, and stained with 400 μl PI in the dark at room temperature for a further 30 min. The stained cells were measured using Epics XL-MCL™ Flow Cytometer (Beckman Coulter), and the data were analyzed using Flowing software (version 2.5.1, Turku Center for Biotechnology, Turku, Finland).

4. Flow cytometry analysis for apoptosis

Flow cytometry cell apoptosis analysis was used to investigate the apoptotic effect of the synthesized compounds. HCT-116 cells were treated with compound **11e** ($1.14 \pm 0.01 \mu\text{M}$) for 24 h, collected by trypsin, centrifuged, washed two successive times with PBS, suspended in 500 μl binding buffer, and double stained with 5 μl Annexin V-FITC and 5 μl PI in the dark at room temperature for 15 min. The stained cells were measured using Epics XL-MCL™ Flow Cytometer and analyzed using Flowing software.

5. *In vitro* immunomodulatory assay of TNF- α and IL-6.

The effects of compound **11e** on the expression of TNF- α and IL-6 were determined using qRT-PCR technique. The quantity of immunomodulatory proteins (TNF- α and IL-6) in control and compound **11e** (at the IC₅₀ concentration)-treated HCT-116 cells was assessed by qRT-PCR (reference). Total RNA from vehicle-treated control (0.01% DMSO) and 10k-treated HCT-116 cells were extracted as-per the manufacturer instructions (RNeasy mini kit, Qiagen, Germany). After RNA extraction, cDNA was prepared using the Revert Aid First Strand cDNA Synthesis kit (Thermo Scientific, USA). Amplification of target cDNA for apoptosis markers and GAPDH [as a normalization (housekeeping) gene] was done using one-step RT-PCR SYBR® Green kit Master Mix (Bio-Rad Laboratories, USA) on Rotor-Gene Q real-time PCR thermal cycler instrument. cDNA (2 μ l aliquots) was mixed with 1 μ l of forward primer, 1 μ l reverse primer, 10 μ l master mixture, and the reaction volume was completed to 20 μ l with nuclease-free water. All experiments were performed in triplicates.

6. Statistical analysis

Graph Pad Prism 6 software was used for statistical evaluation of the grouped data. Values are expressed as the mean \pm SEM of the triplicates of each experiment. p value of less than 0.05 was accepted as statistically significant.

Molecular docking studies and molecular dynamic simulation


MOE 19.0102 software was used in the docking studies, where the binding affinities of target compounds against the ATP binding site of VEGFR-2 TK were evaluated. The 3D crystal structure of VEGFR-2 TK was downloaded from the Protein Data Bank, <http://www.rcsb.org/pdb> (PDB ID: 1YWN: 1.71 Å). At first, water molecules were deleted from the downloaded protein molecule. Energy minimization was performed by applying CHARMM and MMFF94 force fields. The active binding site was identified and prepared for docking protocol. The 2D structures of thalidomide and the target compounds were drawn using ChemBioDraw Ultra 14.0 and saved in MDL-SD file format. The re-docking of the co-crystallized ligand (4-amino-furo[2,3-d]pyrimidine) molecule into the ATP binding site of VEGFR-2 TK validated the docking process. The re-docked pose overlaid with the original one and had the same binding mode which was consistent with the reported mode (**Fig. XXX& XXX**). The re-docked pose had root mean square deviation (RMSD) 0.49 Å and docking score of -10.90 kcal/mol. After opening of the SD file and protonation of the 3D structures, energy was minimized. Preparation of the target structures was

done through optimization of the parameters. The docking process was done using the MOE 19.0102 software and Sorafenib was used as reference. A maximum of 15 conformers was considered for each molecule in the docking analysis. Then, the docking scores of the most ideal pose for each of the docked molecules were recorded (**Table xxx**).


On the other hand, Molecular dynamics simulation of the protein-ligand complexes was performed using GROMACS¹ 2021.1 version and Linux 5.4 package. The GROMOS96 54a7 forcefield was selected as the force field for proteins and the ligand topologies were generated from the PRODRG² server. All the complexes were solvated using simple point charge (SPC) water molecules in a rectangular box. To make the simulation system electrically neutral, the required number of Na⁺ and Cl⁻ ions were added while 0.15 mol/L salt concentrations were set in all the systems. Using the steepest descent method, all the solvated systems were subjected to energy minimization for 5000 steps. Afterwards, NVT (constant number of particles, volume, and temperature) series, NPT (constant number of particles, pressure, and temperature) series, and the production run were conducted in the MD simulation. The NVT and the NPT series were conducted at a 300 K temperature and 1 atm pressure for the duration of 300 ps. V-rescale thermostat and Parrinello-Rahman barostat were selected for the performed simulation. Finally, the production run was performed at 300 K for a duration of 100 ns (nanoseconds). Thereafter, a comparative analysis was performed measuring root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent accessible surface area (SASA) and hydrogen bonds to analyze their stability. The Xmgrace program was used to represent the analyses in the form of plots.

Spectral data of intermediate and final target compounds (3, 4, 5, 6, 8, 9a-d, 11a-e, and 12a-g)


Compound 4




1H NMR 11h




Compound 4




¹H NMR 11h



Compound 4




¹H NMR 11h





Compound 4


7.97
7.95
7.90
7.89
7.80
7.78
7.64
7.62
7.61
7.59




2.18
2.07
2.16
3.30




¹H NMR 11h




Compound 4




¹H NMR (1h)




Compound 4




¹H NMR 11h





Compound 4







¹H NMR 11h


Compound 5



¹H NMR 11h


Compound 5





Compound 5


8.00
7.98
7.91
7.89
7.84
7.82
7.66
7.64
7.63
7.63
7.62
7.62
7.60
7.58
7.58




2.00
2.03
1.99
3.14

9.1 9.0 8.9 8.8 8.7 8.6 8.5 8.4 8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.0 6.9 6.8 6.7 6.6 6.5
f1 (ppm)


10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0



Compound 5



¹H NMR 11h



Compound 5

—197.21
—174.73
—168.73
—160.34

142.88
136.23
133.11
131.80
129.30
129.26
129.07
—122.73
—116.40

—85.99

—27.05

—14.34



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10

f1 (ppm)


11000
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
-1000

¹H NMR 11h


Compound 5




¹³C NMR 11h



Compound 5



¹H NMR 11h




10.10

7.94
7.92
7.85
7.83
7.83
7.76
7.74
7.57
7.56
7.54
7.53


Compound 6

2.53
2.45




f1 (ppm)


¹H NMR 11h



Compound 6




¹H NMR 11h



Compound 6

7.94
7.92
7.85
7.83
7.83
7.76
7.74
7.57
7.56
7.54
7.53




2.02
1.06
1.15
2.16
3.03

8.5 8.4 8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1


f1 (ppm)

7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
-0.5


¹H NMR 11h



Compound 6



¹H NMR 11h




Compound 6

— 197.26 — 174.64 — 168.73 — 160.40 — 142.76 — 136.38 — 132.96 — 131.80 — 129.36 — 129.30 — 129.12 — 122.83 — 116.65

— 86.16


— 27.11

— 14.37



¹H NMR 11h


Compound 6




86.16

27.11

14.37



¹H NMR 11h



Compound 6

— 197.26

— 174.64

— 168.73

— 160.40

— 142.76

— 136.38

— 132.96

— 131.80

— 129.36

— 129.30

— 129.12

— 122.83

— 116.65

0.40

0.35

0.30

0.25

0.20

0.15


0.10

0.05



0.00

205 200 195 190 185 180 175 170 165 160 155 150 145 140 135 130 125 120 115 110 105 100


f1 (ppm)




Compound 8





¹H NMR 11h




Compound 8



Compound 8




¹H NMR 11h



Compound 8

7.85
7.83
7.80
7.79
7.67
7.66
7.58
7.57
7.57
7.57
7.56
7.56
7.55
7.54
7.54
7.54
7.53
7.53




2.07
2.06
2.03
3.06


8.20 8.15 8.10 8.05 8.00 7.95 7.90 7.85 7.80 7.75 7.70 7.65 7.60 7.55 7.50 7.45 7.40 7.35 7.30 7.25 7.20 7.15 7.10 7.05 7.00

f1 (ppm)


¹H NMR 11h




Compound 8



¹H NMR 41h



Compound 8






¹H NMR 11h

—85.61


Compound 8

—14.32







¹H NMR 11h




Compound 9a




¹H NMR 11h




Compound 9a




¹H NMR 11h




Compound 9a




¹H NMR 11h




Compound 9a







¹H NMR 11h




Compound 9a



¹³C NMR 11h




Compound 9a




SAMPLE INFORMATION


Sample Name:	ASL5 Compound 9b	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	
Vial:	14	Acq. Method Set:	Organic
Injection #:	1	Processing Method:	Default
Injection Volume:	2.00 ul	Channel Name:	320.0nm
Run Time:	14.0 Minutes	Proc. Chnl. Descr.:	W2996 FDA 320.0 nm(FDA 190.0 to

Date Acquired: 11/6/2022 5:18:18 AMEET
 Date Processed: 11/6/2022 5:33:06 AMEET




	RT	Area	% Area	Height
1	3.166	27922	0.47	4657
2	11.667	5852346	99.53	337582







¹H NMR 11h




¹H NMR 11h




Compound 9b




¹H NMR 11h




Compound 9b




¹H NMR 11h




Compound 9b







¹H NMR 1H




Compound 9b






RT: 3.94 - 4.35 SM: 11B



NL:
2.90E4
TIC MS
Abdelrahman
n-saleh-
AsL5


Abdelrahman-saleh-AsL5 #135-138 RT: 2.28-2.33 AV: 4 SB: 26 1.21-1.34 , 0.87-1.14 NL: 8.87E1
T: + c EI Full ms [40.00-1000.00]




SAMPLE INFORMATION

Sample Name:	ASL4 Compound 9c	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	
Vial:	13	Acq. Method Set:	Organic
Injection #:	1	Processing Method:	Default
Injection Volume:	2.00 ul	Channel Name:	261.4nm
Run Time:	14.0 Minutes	Proc. Chnl. Descr.:	W2996 FDA 261.4 nm(FDA 190.0 to


Date Acquired: 11/6/2022 6:18:22 AMEET
 Date Processed: 11/6/2022 6:33:43 AMEET



	RT	Area	% Area	Height
1	2.581	50406	1.23	9675
2	2.748	17187	0.42	3193
3	4.609	36709	0.89	4451
4	6.442	3997303	97.46	355748




¹H NMR 11h




Compound 9c


¹H NMR 11h




Compound 9c




1H NMR 11h




Compound 9c




1H NMR 11h



Compound 9c







¹H NMR 11h

— 85.82


— 14.40




Compound 9c




¹H NMR 11h




Compound 9c







¹H NMR 11h




Compound 9d




¹H NMR 11h




Compound 9d




¹H NMR 11h




Compound 9d




¹H NMR 11h



Compound 9d







¹H NMR 11h

81.83


14.38




Compound 9d




¹H NMR 11h




Compound 9d







¹H NMR 11a




Compound 11a




¹H NMR 11h




Compound 11a




¹H NMR 11h




Compound 11a




¹H NMR



Compound 11a




¹H NMR 11h




Compound 11a

85.45


14.94
14.37



¹H NMR 11h




Compound 11a




SAMPLE INFORMATION


Sample Name:	ASZ3 Compound 11b	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	1
Vial:	6	Acq. Method Set:	Organic
Injection #:	1	Processing Method:	Default
Injection Volume:	2.00 ul	Channel Name:	278.9nm
Run Time:	14.5 Minutes	Proc. Chnl. Descr.:	W2996 FDA 278.9 nm(FDA 190.0 to

Date Acquired: 11/5/2022 11:30:47 PMEET
 Date Processed: 11/6/2022 5:22:27 AMEET




	RT	Area	% Area	Height
1	8.603	62358	0.99	5028
2	12.290	6208543	99.01	301317







¹H NMR 11h



Compound 11b




¹H NMR 11h




Compound 11b


— 2.45
— 2.39
~ 2.28
~ 2.24




¹H NMR 11b



Compound 11b



¹H NMR 11h




Compound 11b

174.73
170.13
168.69
163.53
160.40
154.52
148.58
139.59
137.29
136.38
134.50
131.77
130.11
129.28
129.10
127.68
127.12
126.40
123.37
116.54


85.46

14.96
14.15




¹H NMR 11b


Compound 11b




85.46

14.96
14.15







1H NMR 11h



Compound 11b







SAMPLE INFORMATION

Sample Name:	ASZ8 Compound 11c	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	
Vial:	10	Acq. Method Set:	Organic
Injection #:	1	Processing Method:	Default
Injection Volume:	2.00 ul	Channel Name:	320.0nm@1
Run Time:	14.0 Minutes	Proc. Chnl. Descr.:	W2996 FDA 320.0 nm(FDA 190.0 to


Date Acquired: 11/6/2022 5:39:21 AMEET
 Date Processed: 11/6/2022 5:48:29 AMEET




	RT	Area	% Area	Height
1	2.992	297834	3.75	44622
2	3.679	7639522	96.25	1142412




¹H NMR 11h




Compound 11c







Compound 11c




¹H NMR 11h




Compound 11c




¹H NMR 11h



Compound 11c



¹H NMR 11h



Compound 11c

85.45

56.51


19.02

14.30

100 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0

f1 (ppm)


3200
3000
2800
2600
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
-200




RT: 2.72 - 2.91 SM: 11B

Compound 11c

NL:
5.05E3
TIC MS
Abdelrahma
n-saleh-
Asz8




Abdelrahman-saleh-Asz8 #217-220 RT: 3.65-3.70 AV: 4 SB: 26 1.21-1.34 , 0.87-1.14 NL: 1.09E2
T: + c EI Full ms [40.00-1000.00]





SAMPLE INFORMATION

Sample Name:	ASZ5 Compound 11d	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	1
Vial:	8	Acq. Method Set:	Organic
Injection #:	1	Processing Method:	Default
Injection Volume:	2.00 ul	Channel Name:	318.0nm
Run Time:	14.5 Minutes	Proc. Chnl. Descr.:	W2996 FDA 318.0 nm(FDA 190.0 to
Date Acquired:	11/6/2022 12:01:19 AMEET		
Date Processed:	11/6/2022 5:21:16 AMEET		




RT	Area	% Area	Height	
1	5.113	26989	1.16	3282
2	8.619	125681	5.42	9731
3	10.943	2164478	93.41	117977







¹H NMR 11d




Compound 11d




¹H NMR 11h





Compound 11d






Compound 11d








¹H NMR 11h




Compound 11d



Compound 11e




¹H NMR 11h




Compound 11e


¹H NMR 11h




Compound 11e




¹H NMR 11h




Compound 11e




¹H NMR 11h



Compound 11e







1H NMR 11h

86.39


14.41

13.77


Compound 11e



¹H NMR 11h




Compound 11e





SAMPLE INFORMATION

Sample Name:	ASZM7 Compound 12a	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	1
Vial:	17	Acq. Method Set:	Organic1
Injection #:	1	Processing Method:	Default1
Injection Volume:	2.00 ul	Channel Name:	280.0nm
Run Time:	14.5 Minutes	Proc. Chnl. Descr.:	W2996 FDA 280.0 nm(FDA 190.0 to
Date Acquired:	11/6/2022 2:34:04 AMEET		
Date Processed:	11/6/2022 5:08:35 AMEET		




	RT	Area	% Area	Height
1	5.930	40958	0.62	4091
2	9.945	6609864	99.38	395628







¹H NMR 11h




Compound 12a




¹H NMR 11h





Compound 12a






Compound 12a







¹H NMR 11h




Compound 12a





¹H NMR 11h




Compound 12a









¹H NMR 11h




Compound 12b




¹H NMR 11h




Compound 12b




¹H NMR 11h





Compound 12b






¹H NMR 11b


compound 12b




¹H NMR 11h




compound 12b




¹H NMR 11h




compound 12b




¹H NMR 11h




compound 12b



¹H NMR 11h




compound 12b




SAMPLE INFORMATION


Sample Name:	ASZMB Compound 12c	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	1
Vial:	20	Acq. Method Set:	Organic1
Injection #:	1	Processing Method:	Default
Injection Volume:	2.00 ul	Channel Name:	275.0nm
Run Time:	14.5 Minutes	Proc. Chnl. Descr.:	W2996 FDA 275.0 nm(FDA 190.0 to

Date Acquired: 11/5/2022 9:59:08 FMEET
 Date Processed: 11/6/2022 5:29:15 AMEET




	RT	Area	% Area	Height
1	8.878	2840951	100.00	204997







¹H NMR 11h




Compound 12c




¹H NMR 11h




Compound 12c




¹H NMR 11h




Compound 12c







¹H NMR 1h




Compound 12c




¹H NMR 11h




Compound 12c







¹H NMR 11h




¹H NMR 11h




Compound 12d



¹H NMR 11h



Compound 12d



¹H NMR 11h



— 174.61
— 168.58
— 164.39
— 163.07
— 160.56

138.15
137.19
136.39
131.65
129.95
129.19
129.05
129.01
128.92
125.36
124.02
123.93
123.70
122.14
116.50

— 85.11

15.04
14.21

Compound 12d






¹H NMR 11h

85.11


15.04
14.21


Compound 12d






¹H NMR 11h







¹H NMR 11h




Compound 12e



1H NMR 11h



Compound 12e



¹H NMR 11h

8.14

7.97

7.96

7.85

7.83

7.66

7.64

7.62

7.61

7.59

7.58

7.58

7.55

7.54

7.53

7.43

7.42

7.40

7.39

7.37


7.00

6.99


6.96

6.94


6.93




Compound 12e




¹H NMR 11h



Compound 12e







¹H NMR 11h

85.13


14.42
14.30




Compound 12e



¹H NMR 11h




Compound 12e




SAMPLE INFORMATION

Sample Name:	ASZM4	Compound 12f	Acquired By:	System
Sample Type:	Unknown		Sample Set Name:	1
Vial:	19		Acq. Method Set:	Organic1
Injection #:	1		Processing Method:	Default
Injection Volume:	2.00 ul		Channel Name:	286.0nm
Run Time:	10.0 Minutes		Proc. Chnl. Descr.:	W2996 FDA 286.0 nm(FDA 190.0 to


Date Acquired: 11/6/2022 7:47:03 AMEET
 Date Processed: 11/6/2022 10:26:57 AMEET




	RT	Area	% Area	Height
1	1.985	179325	2.24	32588
2	2.086	230882	2.88	33692
3	3.945	7599646	94.88	1088143




¹H NMR 11h



Compound 12f



¹H NMR 11h



Compound 12f

—2.47

—2.38

2.82


2.75

5.0 4.8 4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 2.0 1.8 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0


f1 (ppm)

4500
4000
3500
3000
2500
2000
1500
1000
500
0


¹H NMR 11h




Compound 12f



¹³C NMR 12f




Compound 12f




¹H NMR 11h

85.10


14.80
14.21




Compound 12f




¹H NMR 11h




Compound 12f




RT: 1.98 - 2.33 SM: 11B




NL:
1.30E4
TIC MS
Abdelrahma
n-saleh-
AsZM4




Abdelrahman-saleh-AsZM4 #92 RT: 1.56 AV: 1 SB: 26 1.21-1.34 , 0.87-1.14 NL: 4.15E2
T: + c EI Full ms [40.00-1000.00]







¹H NMR 11h




¹H NMR 11h




Compound 12g




¹H NMR 11h




Compound 12g




¹H NMR 11h




Compound 12g



¹H NMR 11g



Compound 12g



¹H NMR 11h

— 174.61

— 168.57

— 164.59

— 160.57

— 152.66

— 139.18

— 138.35

— 136.43

— 131.63

— 130.31

— 129.19

— 129.02

— 128.76

— 124.79


— 123.26

— 121.97

— 120.53

— 116.52

— 113.00



Compound 12g

